Publicaciones en las que colabora con Montserrat García García (28)

2023

  1. Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database

    European Journal of Clinical Pharmacology, Vol. 79, Núm. 5, pp. 679-685

  2. Hypersensitivity reactions associated with iron isomaltoside and ferric carboxymaltose

    European Journal of Internal Medicine

2022

  1. Subacute thyroiditis and COVID-19 vaccines: a case/non-case study

    Endocrine, Vol. 77, Núm. 3, pp. 480-485

2021

  1. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study

    European Neuropsychopharmacology, Vol. 50, pp. 107-111

  2. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database

    Journal of Clinical Pharmacology, Vol. 61, Núm. 2, pp. 187-192

  3. Tramadol-induced hiccups: a case–noncase study in the European pharmacovigilance database

    Therapeutic Advances in Drug Safety, Vol. 12

2020

  1. Pharmacovigilance in the times of COVID-19

    Gaceta Medica de Bilbao

2019

  1. Antipsychotics and pituitary tumors: An analysis of the European pharmacovigilance database (EudraVigilance)

    International Clinical Psychopharmacology, Vol. 34, Núm. 2, pp. 89-92

  2. Reply: On the safety of intravenous iron formulations

    Medicina Clinica

2018

  1. Aripiprazole and impulse control disorders: Higher risk with the intramuscular depot formulation?

    International Clinical Psychopharmacology, Vol. 33, Núm. 1, pp. 56-58

  2. Ciclosporin and chorea: a new association?

    Journal of Neurology

2017

  1. Clozapine-Induced Cardiomyopathy in Parkinson's Disease

    Movement Disorders Clinical Practice

  2. Hiccups in Parkinson’s disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature

    European Journal of Clinical Pharmacology, Vol. 73, Núm. 9, pp. 1159-1164

2016

  1. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 3, pp. 368-370

  2. Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de Farmacovigilancia

    Medicina Clinica, Vol. 147, Núm. 10, pp. 461-464

2015

  1. Adverse reactions to antipsychotics in parkinson disease: An analysis of the Spanish Pharmacovigilance database

    Clinical Neuropharmacology, Vol. 38, Núm. 3, pp. 69-84

  2. Possible interaction between letrozole and long-acting injectable zuclopenthixol

    Nordic Journal of Psychiatry, Vol. 69, Núm. 1, pp. 79-80

2014

  1. Acute adverse reactions to iopromide vs iomeprol: A retrospective analysis of spontaneous reporting from a radiology department

    British Journal of Radiology, Vol. 87, Núm. 1033

2013

  1. Antipsychotics and seizures: Higher risk with atypicals?

    Seizure, Vol. 22, Núm. 2, pp. 141-143

  2. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?

    Current drug safety, Vol. 8, Núm. 1, pp. 63-68